Key Developments: Alere Inc (ALR)

ALR on New York Consolidated

40.25USD
16 Sep 2014
Price Change (% chg)

$-0.89 (-2.16%)
Prev Close
$41.14
Open
$41.05
Day's High
$41.05
Day's Low
$40.01
Volume
2,276,077
Avg. Vol
708,952
52-wk High
$43.00
52-wk Low
$30.14

Search Stocks

Latest Key Developments (Source: Significant Developments)

Alere Inc declares cash dividend on its series B convertible perpetual preferred stock
Tuesday, 2 Sep 2014 10:45pm EDT 

Alere Inc:Says that it has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock.Says the dividend is payable on Oct. 15, 2014 to holders of record of Series B stock at the close of business on Oct. 1, 2014.  Full Article

Alere appoints interim chief executive and president
Tuesday, 1 Jul 2014 07:00am EDT 

Alere Inc:Ron Zwanziger resigns as chief executive officer, president and director effective immediately.Appoints chief operating officer Namal Nawana as interim chief executive and president.  Full Article

Alere Inc opts not to pursue initial public offering by BBI Diagnostics Group plc
Wednesday, 18 Jun 2014 11:30am EDT 

Alere Inc:Elects not to proceed at this time with its previously announced plans to pursue an initial public offering in the United Kingdom of the ordinary shares of BBI Diagnostics Group plc, or BBI Diagnostics.Intends to seek greater value for businesses of BBI Diagnostics than could be realized under current equity market conditions in the United Kingdom.Alere remains committed to its previously communicated strategy of divesting of non-core assets and to the use of proceeds from such divestitures to reduce its outstanding indebtedness.  Full Article

Alere Inc receives FDA clearance for Alere i Influenza A and B Test
Monday, 16 Jun 2014 08:30am EDT 

Alere Inc:Receives clearance from tU.S. Food and Drug Administration (FDA) for Alere i Influenza A & B test, the molecular test to detect and differentiate influenza A and B virus in less than 15 minutes.All specimens generating discrepant results between the Alere i Influenza A & B test and viral culture were tested using an FDA cleared RT-PCR assay to confirm influenza status.Molecular testing involves the extraction and analysis of DNA or RNA strands to detect sequences associated with viral and bacterial causes of infections.  Full Article

Alere Inc declares cash dividend on its series B convertible perpetual preferred stock
Thursday, 15 May 2014 06:08pm EDT 

Alere Inc:Declares cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock.Dividend is payable on July 15, 2014 to holders of record of Series B stock at the close of business on July 1, 2014.  Full Article

Alere Inc initiates voluntary urgent product recall of Alere INRatio2 PT/INR
Tuesday, 6 May 2014 08:30am EDT 

Alere Inc:Initiated voluntary Class 1 recall in U.S. of Alere INRatio2 PT/INR Professional Test Strips (PN 99008G2).This action is result of complaints of patients who had therapeutic or near therapeutic INR with Alere INRatio2 PT/INR Professional Test Strip but significantly higher INR (outside of therapeutic range) when performed by central laboratory.  Full Article

Alere Inc Announces separation of chief executive officer and chairman roles
Monday, 5 May 2014 08:30am EDT 

Alere Inc:Says it has separated the roles of chairman of the board and chief executive officer.Says board has unanimously elected Gregg J. Powers as Chairman of the Board of Alere.While Ron Zwanziger will continue as president, chief executive officer and a member of the board.  Full Article

Alere Inc announces plan for IPO by subsidiary, BBI Diagnostics Group plc
Tuesday, 29 Apr 2014 07:54am EDT 

Alere Inc:To pursue IPO of BBI Diagnostics Group plc, subsidiary in UK.Net proceeds will be used by Alere to pay down outstanding debt.Price range for the offering has not yet been determined.BBI Diagnostics will apply to UK Financial Conduct Authority, or FCA, for shares to be admitted to standard listing segment of official list of FCA and to trading on Main Market of LSE.  Full Article

Alere Inc declares cash dividend on its series B convertible perpetual preferred stock
Monday, 3 Mar 2014 07:33pm EST 

Alere Inc:declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock.Says the dividend is payable on April. 15, 2014 to holders of record of Series B stock at the close of business on April. 1, 2014.  Full Article

Miraculins Inc and Alere Inc Shift Focus of Endoglin Program from Sub-License to Supply Agreement
Thursday, 30 Jan 2014 08:16pm EST 

Miraculins Inc:Says that Alere Inc. has elected not to proceed further in the direct commercial development of a professional diagnostic product for the biomarker Endoglin.Says instead it will support Miraculins in seeking commercialization opportunities for Endoglin by supplying key antibodies that were developed by Alere.Says as part of this decision, Alere has declined to proceed further with its Endoglin license from Miraculins.And the parties have agreed to work to enhance Miraculins' rights to receive a secure supply of high quality, proprietary Endoglin reagents manufactured by Alere.  Full Article

Deals of the day- Mergers and acquisitions

(Adds SABMiller, Orange, BNP Paribas, AbbVie, America Movil, Microsoft, Club Mediterranee, JSW Steel, Alere, GFI Group, AngloGold Ashanti, Qatar National Bank and Telekom)

Search Stocks